We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for the Treatment of HER-2/Neu-Overexpressing Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00399529
Recruitment Status : Completed
First Posted : November 15, 2006
Last Update Posted : December 13, 2012
American Cancer Society, Inc.
Avon Foundation
Cancer Treatment Research Foundation
The Commonwealth Fund
United States Department of Defense
Genentech, Inc.
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Primary Completion Date : February 2010
  Study Completion Date : February 2010
  Certification or Request for Extension to Delay Results Submission: November 29, 2012